Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth, Trends

News provided by

Jul 16, 2014, 07:56 ET

LONDON, July 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth, Trends

https://www.reportbuyer.com/product/2042908/Pharmacovigilance-Market-[Clinical-Trial-Phases-Pre-Clinical-Studies-Phase-I-Phase-II-Phase-III-Phase-IV-or-Post-Marketing-Surveillance-and-Service-Providers-In-House-and-Contract-Outsourcing]---Global-Industry-Analysis-Size-Share-Growth-Trends.html

A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting.

The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service.

The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations.

The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW).

The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions.

The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others.

Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics
3.1 Introduction
3.1.1 Drivers
3.1.1.1 Rise in number of drug consumption
3.1.1.2 Rise in drug toxicity cases producing significant morbidity and mortality
3.1.1.3 Embracing new technologies to mitigate risk
3.1.1.4 Rise in adoption of pharmacovigilance outsourcing services
3.1.1.5 Globalization of drug development with shift from manufacturing activities from high cost to low cost regions
3.1.2 Restraints
3.1.2.1 Stringent and varied regulatory approval processes
3.1.3 Challenges
3.1.3.1 Lack of availability of skilled labor
3.2 Porter's Five Force Analysis: Global Pharmacovigilance Market
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitutes
3.2.5 Competitive Rivalry
3.3 Market Attractiveness Analysis of the Global Pharmacovigilance Market, by Geography
3.3.1 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography

Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases
4.1 Overview
4.1.1 Preclinical Studies
4.1.1.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
4.1.2 Phase I trial
4.1.2.1 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
4.1.3 Phase II trial
4.1.3.1 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
4.1.4 Phase III trial
4.1.4.1 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
4.1.5 Phase IV trial (Post marketing surveillance)
4.1.5.1 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods
5.1 Overview
5.1.1 Spontaneous Reporting
5.1.1.1 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 – 2019 (USD Million)
5.1.2 Targeted Reporting
5.1.2.1 Global Targeted Drug Safety Reporting Market Revenue, 2011 – 2019 (USD Million)
5.1.3 Cohort Event Monitoring
5.1.3.1 Global Cohort Event Monitoring Market Revenue, 2011 – 2019 (USD Million)
5.1.4 EHR Monitoring
5.1.4.1 Global Electronic Health Records (EHR) Monitoring Market Revenue, 2011 – 2019 (USD Million)
5.1.5 Intensified ADR Reporting
5.1.5.1 Global Intensified ADR Reporting Market Revenue, 2011 – 2019 (USD Million)

Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers
6.1 Overview
6.1.1 In-House
6.1.1.1 Global In-House Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
6.1.2 Contract Outsourcing
6.1.2.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Overview
7.1.1 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
7.2 North America
7.2.1 North America Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
7.3 Europe
7.3.1 Europe Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
7.4 Asia Pacific
7.4.1 Asia-Pacific Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
7.5 Rest of the World
7.5.1 Rest of the World Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)

Chapter 8 Global Pharmacovigilance Market Share Analysis
8.1 Market Share Analysis by Key Players of Global Pharmacovigilance Market
8.1.1 Global CRO Market Share Analysis, by Key Players, 2012 (%)

Chapter 9 Recommendations
9.1 Success Strategies
9.1.1 Developing Strategic Alliances and Partnerships With CROs and Life Science BPOs Companies
9.1.2 Hub and Spoke model to optimize drug safety
9.1.3 Enhancing operational activities for better outcomes
9.1.4 Expand Market into Emerging Countries

Chapter 10 Company Profiles
10.1 Accenture, Plc
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.4.1 Mergers and acquisitions
10.1.5 Recent Developments
10.2 Bristol-Myers Squibb
10.2.1 Company Profile
10.2.2 Financial overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.4.1 Strategic collaboration
10.2.4.2 Research and Development Initiatives
10.2.4.3 Recent Developments
10.3 Clinquest Group B.V.
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Business Strategies
10.3.3.1 Strategic partnership
10.3.4 Recent Developments
10.4 Cognizant Technology Solutions
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.4.1 Expansion of geographical footprint
10.4.4.2 Expansion of product portfolio
10.4.4.3 Highly-skilled manpower
10.4.4.4 Strategic acquisitions
10.4.5 Recent Developments
10.5 Covance, Inc.
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.4.1 New product development and innovation
10.5.4.2 Agreements and collaborations
10.5.4.3 Strategic acquisitions
10.5.4.4 Geographical expansion of business
10.5.5 Recent Developments
10.6 GlaxoSmithKline (GSK)
10.6.1 Company Overview
10.6.2 Financial overview
10.6.3 Product Portfolio
10.6.4 Business strategies
10.6.4.1 Research and development initiatives
10.6.4.2 Direct to Consumer Advertising
10.6.4.3 Mergers and acquisitions
10.6.5 Recent developments
10.7 ICON, Plc
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.4.1 Business expansion in APAC region
10.7.4.2 Expansion of services offered
10.7.5 Recent Developments
10.8 iGATE Corporation
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.4.1 Strategic Acquisition
10.8.5 Recent Developments
10.9 iMEDGlobal Corporation
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Business Strategies
10.9.3.1 Geographical Expansion
10.9.4 Recent Developments
10.10 Infosys
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.4.1 Extensive product portfolio
10.10.4.2 Geographical expansion of business
10.10.5 Recent Developments
10.11 inVentiv Health Inc.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Business Strategies
10.11.3.1 Strategic Partnership
10.11.3.2 Strategic Acquisition
10.11.4 Recent Developments
10.12 Johnson and Johnson
10.12.1 Company Profile
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.4.1 Extensive Research and Development Investments
10.12.4.2 Strategic Collaborative Arrangements
10.12.4.3 Recent Developments
10.13 Novartis International AG
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategy
10.13.4.1 Mergers and Acquisitions
10.13.5 Recent Developments
10.14 OptumInsight, Inc.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Business Strategies
10.14.3.1 Strategic product launch
10.14.3.2 Strategic collaboration
10.14.4 Recent Developments
10.15 Parexel International Corporation
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.3.1 Strong presence in Asia and emerging markets
10.15.3.2 Strategic alliances
10.15.3.3 Mergers & Acquisitions
10.15.4 Recent Developments
10.16 Pfizer, Inc.
10.16.1 Company Overview
10.16.2 Financial Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.16.4.1 Acquisitions
10.16.5 Recent Developments
10.17 Pharmaceutical Product Development, Inc. (PPD, Inc.)
10.17.1 Company Overview
10.17.2 Product Portfolio
10.17.3 Business Strategies
10.17.3.1 Expanding geographic presence
10.17.3.2 Incorporation of innovative technologies
10.17.3.3 Strategic acquisitions
10.17.3.4 New product launch and innovation
10.17.4 Recent Developments
10.18 PRA International, Inc.
10.18.1 Company Overview
10.18.2 Product Portfolio
10.18.3 Business Strategies
10.18.3.1 Mergers and acquisitions
10.18.4 Recent Developments
10.19 Quantum Solutions India
10.19.1 Company Overview
10.19.2 Product Portfolio
10.19.3 Business Strategies
10.19.3.1 Strategic Collaborations
10.20 Quintiles Transnational Corporation
10.20.1 Company Overview
10.20.2 Financial Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
10.20.4.1 Expansion of services
10.20.4.2 Acquisitions and partnerships
10.20.4.3 Innovation in services offered
10.20.5 Recent Developments
10.21 F. Hoffmann-La Roche Ltd.
10.21.1 Company Overview
10.21.2 Financial Overview
10.21.3 Product Portfolio
10.21.4 Business Strategies
10.21.4.1 Licensing Agreement
10.21.4.2 Product portfolio expansion
10.22 Sanofi Aventis
10.22.1 Company Overview
10.22.2 Financial Overview
10.22.3 Product Portfolio
10.22.4 Business Strategy
10.22.4.1 Renewal of cooperation protocol
10.22.4.2 Recent developments
10.23 Synowledge LLC
10.23.1 Company Overview
10.23.2 Product Portfolio
10.23.3 Business Strategies
10.23.3.1 Geographical Expansion
10.23.3.2 Strategic Partnership
10.23.4 Recent Developments
10.24 United BioSource Corporation
10.24.1 Company Overview
10.24.2 Product Profiling
10.24.3 Business Strategies
10.24.3.1 Strategic acquisitions
10.25 Wipro Limited
10.25.1 Company Overview
10.25.2 Financial Overview
10.25.3 Product Portfolio
10.25.4 Business Strategies
10.25.4.1 Geographical expansion

List of Figures

FIG. 1 Drug Safety From Molecule to Market
FIG. 2 Global Pharmacovigilance : Market Segmentation
FIG. 3 Global Pharmacovigilance Market, by Type of Service Providers, 2012 (USD Million)
FIG. 4 Global Pharmacovigilance Market, by Type of Clinical Trial Phases, 2012 (USD Million)
FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2012 (USD Million)
FIG. 6 Global Pharmacovigilance Market: Drivers and Restraints
FIG. 7 Porter's Five Force Analysis: Global Pharmacovigilance Market
FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography
FIG. 9 Safety Services : Product Lifecycle
FIG. 10 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 14 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 15 Comparison of Methods: Pharmacovigilance reporting
FIG. 16 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 – 2019 (USD Million)
FIG. 17 Global Targeted Drug Safety Reporting Market Revenue, 2011 – 2019 (USD Million)
FIG. 18 Global Cohort Event Monitoring Market Revenue, 2011 – 2019 (USD Million)
FIG. 19 Global Electronic Health Records (HER) Monitoring Market Revenue, 2011 – 2019 (USD Million)
FIG. 20 Global Intensified ADR Reporting Market Revenue, 2011 – 2019 (USD Million)
FIG. 21 End-to-End Safety Across the Lifecycle
FIG. 22 Global In-House Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 23 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 24 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
FIG. 25 North America Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 26 Europe Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 Asia-Pacific Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 28 Rest of the World Pharmacovigilance Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 Global CRO: Market Share, by Key Players, 2012 (%)
FIG. 30 Accenture, Plc.: Annual Revenue (USD Billion) 2010 – 2012
FIG. 31 Bristol-Myers Squibb: annual sales revenue, USD million, 2010 – 2012
FIG. 32 Cognizant Technology Solutions: Annual Sales Revenue, USD Million (2010– 2012)
FIG. 33 COVANCE, Inc.: Annual Sales Revenue, USD Billion (2010– 2012)
FIG. 34 GSK, Annual Sales Revenue, 2010 – 2012 (USD million) (Conversion rate: 1 GBP = 1.6651 USD)
FIG. 35 ICON, PLC: Annual Sales Revenue, USD Million (2010– 2012)
FIG. 36 iGATE Corporation, Annual Revenue: 2010 – 2012 (USD Million)
FIG. 37 Infosys: Annual Sales Revenue, USD Million (2010– 2012)
FIG. 38 Johnson and Johnson: annual sales revenue, USD million, 2010 – 2012
FIG. 39 Novartis International AG., Annual Sales: 2010 – 2012 (USD Million)
FIG. 40 Parexel International Corporation: Annual Sales Revenue, USD Million (2010– 2012)
FIG. 41 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 42 Quintiles Transnational Corporation: Annual Sales Revenue, USD Billion (2010– 2012)
FIG. 43 F. Hoffmann-La Roche Ltd., Annual Revenue: 2010 – 2012 (USD Million) (1 CHF = 1.09 USD)
FIG. 44 Sanofi: Annual Sales Revenue, 2010 – 2012 (USD million)
FIG. 45 Wipro Limited: Annual Revenue (USD Million) 2010 – 2012

List of Tables

TABLE 1 Market Snapshot : Pharmacovigilance Market
TABLE 2 List of Drugs Withdrawn Recently:
TABLE 3 Global Pharmacovigilance Market Revenue, By Type of Clinical Trial Phases, 2011 – 2019 (USD Million)
TABLE 4 Global Pharmacovigilance Market Revenue, By Type of Methods, 2011 – 2019 (USD Million)
TABLE 5 Global Pharmacovigilance Market Revenue, By Type of Service Providers, 2011 – 2019 (USD Million)
TABLE 6 Global Pharmacovigilance Market Revenue, By Geography, 2011 – 2019 (USD Million)

Read the full report:
Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth, Trends

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer